.svg){kind=logo}
Arterial hypertension is the most prevalent modifiable risk factor associated with cardiovascular morbidity and mortality. Although antihypertensive drugs are widely available, in many patients blood pressure control to guideline-recommended target values is not achieved, also because non-adherence to medical therapy is frequently found. Several device-based approaches have been intriduced to lower blood pressure; most of these strategies aim to modulate autonomic nervous system activity. Clinical trials have moved from including patients with resistant hypertension receiving intensive pharmacological treatment to including patients with mild-to-moderate hypertension in the presence or absence of antihypertensive medications. Renal sympathetic denervation is the most extensively investigated device-based therapy for hypertension, and randomized, sham-controlled trials have provided proof-of-principle data for its blood pressure-lowering efficacy. During the lecture, the most recent clinical advancement in hypertension management will be discusssed.
felix.mahfoud@uks.eu
Veranstaltungsort: Universitätsklinikum des Saarlandes, Kirrberger Straße 100, Hörsaal Gebäude 45, 66424 Homburg
Kontakt: office.luzhetskyy@uni-saarland.de
Vorsitzender der DPhG Landesgruppe Saar: Prof. Dr. Andriy Luzhetskyy
